Author: van Griensven, Johan; De Weiggheleire, Anja; Delamou, Alexandre; Smith, Peter G.; Edwards, Tansy; Vandekerckhove, Philippe; Bah, Elhadj Ibrahima; Colebunders, Robert; Herve, Isola; Lazaygues, Catherine; Haba, Nyankoye; Lynen, Lutgarde
Title: The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field Document date: 2016_1_1
ID: riw5xs3j_12
Snippet: In conclusion, whereas the data on ZMapp provide proof of concept, clinical data on and experience with convalescent blood products for the treatment of EVD are very limited. Consequently, WHO prioritized the need to evaluate CP in clinical trials, with the aim to determine its efficacy, safety, and feasibility. Notably, these interventions can be organized by harnessing or increasing existing national capacities quickly within the affected count.....
Document: In conclusion, whereas the data on ZMapp provide proof of concept, clinical data on and experience with convalescent blood products for the treatment of EVD are very limited. Consequently, WHO prioritized the need to evaluate CP in clinical trials, with the aim to determine its efficacy, safety, and feasibility. Notably, these interventions can be organized by harnessing or increasing existing national capacities quickly within the affected countries, without the complications or limitations associated with shipping commercial products, which are often in limited supply.
Search related documents:
Co phrase search for related documents- blood product and clinical trial: 1, 2, 3
- blood product and clinical trial CP evaluate: 1
- blood product and convalescent blood product: 1, 2
- blood product and CP evaluate: 1
- blood product and limited supply: 1
- blood product and national capacity: 1
- clinical trial and concept proof: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- clinical trial and concept proof provide: 1, 2
- clinical trial and CP evaluate: 1, 2, 3, 4, 5
- clinical trial and EVD treatment: 1
- clinical trial and feasibility safety: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- clinical trial and feasibility safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- clinical trial and limited supply: 1
- clinical trial and national capacity: 1, 2, 3, 4
- clinical trial CP evaluate and CP evaluate: 1
- commercial product and concept proof: 1
- concept proof and EVD treatment: 1
Co phrase search for related documents, hyperlinks ordered by date